Johnson & Johnson Vision Launches New ACUVUE® OASYS MAX 1-Day

Tuesday, September 20 2022 | 11 h 30 min | New Products, News, OptikTech, Press Release

Johnson & Johnson Vision Care, Inc. announced the launch of its newest innovation, ACUVUE® OASYS MAX 1-Day contact lenses and ACUVUE® OASYS MAX 1-Day MULTIFOCAL contact lenses for presbyopia.

Designed with a combination of new technologies to help meet the needs of digitally intense lifestyles: TearStable™ Technology and OptiBlue™ light filter. TearStable™ Technology is designed to maximize tear-film stability and lock in moisture for exceptional all-day comfort.The OptiBlue™ light filter has the highest-level blue-violet filter in the industry at 60% to reduce light scatter for exceptional visual clarity, day to night. In addition, ACUVUE® OASYS MAX 1-Day lenses block 99.9% UVA rays and 100% UVB rays.

“Life has changed, post-pandemic. With more time spent on digital devices, we designed these contact lenses by listening to patients and eye care professionals’ feedback to address lifestyle requirements and help prevent dry and tired eyes from becoming normalized,” said John Buch, OD, Senior Principal Research Optometrist, Johnson & Johnson Vision. “Our new ACUVUE® OASYS MAX 1-Day contact lenses help reduce discomfort by providing visual clarity with new technologies to filter blue-violet light, which comes from many sources, including digital screens and travels in short wavelengths and scatters more which can lead to eye discomfort and quality of vision.”

For patients with presbyopia, ACUVUE® MAX 1-Day OASYS MULTIFOCAL contact lenses provide crisp, clear vision at all distances and in all lighting conditions, as well as all-day comfort. The lenses combine the same two powerful technologies – TearStable™ Technology and the OptiBlue™ light filter – plus PUPIL OPTIMIZED DESIGN technology, which tailors 100% of parameters to pupil size variations across both age and refraction compared to less than 2% for the leading competitor. This is the same technology that is available across all ACUVUE® Multifocal contact lenses.

Earlier this year, ACUVUE® OASYS MAX 1-Day and ACUVUE® OASYS MAX 1-Day MULTIFOCAL received U.S. Food & Drug Administration (FDA) clearance, Health Canada approval and completed CE Mark activities for its latest contact lens innovation.

Click HERE for the full press release.